Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous...
3 insider purchases on record · latest filing 2022-11-07.
Insiders have also filed 594 sale transactions at NUVL.